• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Drugs in Development

To test new drugs and treatments for ALS/MND, researchers and pharmaceutical companies must perform clinical trials. A clinical trial is a therapeutic or observational research study to test whether a new drug or therapy is safe and effective for use in humans. Prior to any clinical trial, a drug must pass through a series of steps. 

For ALS/MND, there are many potential drugs and therapies currently undergoing clinical trials. Clinical trials are essential to new drug approvals. However, enrollment in a clinical trial should always be voluntary. People living with ALS/MND must consent prior to enrollment and have the right to know all pertinent details surrounding the trial.

Clinical Trial Information

Here are links to databases of known clinical trials for ALS/MND.

  • ALS/MND Clinical Trial Navigator: The ALS Therapy Development Institute created the ALS Trial Navigator is a comprehensive resource for making informed decisions about participating in ALS/MND clinical trials. Use this innovative tool learn about clinical trials and get a personalized list of ALS/MND trials based on your eligibility and preferences. (Language: English)
  • ALS International Clinical Trial Database: The Associazione conSLAncio Onlus created the ALS/MND International Clinical Trial Database. Built on a multi-lingual website, this features users to view the current status of clinical trials taking place at sites in, or close to, Italy. Each trial is linked to the official trial registry where users can directly access study objectives, eligibility criteria and study contacts. (Language: Italian)
  • HEALEY ALS Platform Trial: The HEALEY ALS Platform Trial aims to accelerate the process of drug development and the path for effective treatment for ALS/MND by testing multiple drugs simultaneously and adaptively. This design has been seen to be successful in cancer trials. Participants will have an equal chance to be randomized to all regimens that are active at the time of screening. Once randomized to a regimen, participants will be randomized to receive either the study drug or placebo. New regimens will be continuously added as new investigational products become available. The trial is recruiting in the United States only and will enroll additional participants as each new regimen is available. (Language: English)

Information on Drugs in Clinical Trial

Here are briefing notes from the International Alliance’s Scientific Advisory Council on drugs and therapies currently being researched.

SPG302

Masitinib

Pridopidine

NP001

Neuronata-R / Lenzumestrocel

Ulefnersen

NurOwn

CNM-Au8

AstroRx

ILB

PrimeC

SOD1-Targeted Therapies & Trials

Regulatory T Cell Enhancing Therapies

C9orf72 Therapies and Trials

Primary Sidebar

Drugs in Development

  • AB Science – Masitinib
  • NurOwn
  • Clene Nanomedicine – CNM-Au8
  • ILB
  • Kadimastem – AstroRx
  • Neuronata-R / Lenzumestrocel
  • NeuroSense – PrimeC
  • NP001
  • Prilenia Therapeutics – Pridopidine
  • SOD1 Therapies & Trials
  • SPG302
  • Regulatory T Cell Enhancing Therapies
  • Ulefnersen

  • Ywan Dierick, Belgium

    Ywan Dierick, Belgium

  • Steven Spencer, New Zealand

    Steven Spencer, New Zealand

  • Michel Perrozzo, France

    Michel Perrozzo, France

  • Ian Gale, Australia

    Ian Gale, Australia

  • Ana Lilia Rodriguez, Mexico

    Ana Lilia Rodriguez, Mexico

  • Cassio Fernando da Silva, Brazil

    Cassio Fernando da Silva, Brazil

  • Carlos Alberto Arango, Colombia

    Carlos Alberto Arango, Colombia

  • Liam Dwyer, England

    Liam Dwyer, England

  • Wilfried Leusing, Germany

    Wilfried Leusing, Germany

  • Purningam Jacob, India

    Purningam Jacob, India

  • Susan Anderson, USA

    Susan Anderson, USA

  • Roy Taylor, Ireland

    Roy Taylor, Ireland
    roy

  • Maurice Leclerc, Canada

    Maurice Leclerc, Canada

  • Malu Araujo Ribeiro, Brazil

    Malu Araujo Ribeiro, Brazil

  • Roxana Canova, Argentina

    Roxana Canova, Argentina

  • Liam Dwyer, England

    Liam Dwyer, England

  • Dorette Lüdi, Switzerland

    Dorette Lüdi, Switzerland

  • Lucy Lintott, Scotland

    Lucy Lintott, Scotland

  • Dr. Janmejay Pradhan, India

    Dr. Janmejay Pradhan, India

  • Semra Gokalp, Turkey

    Semra Gokalp, Turkey

  • Joanne Pratt, Australia

    Joanne Pratt, Australia

  • Mauricio Dorin, Argentina

    Mauricio Dorin, Argentina

  • Elkin Ramiro Gaviria Muñoz, Colombia

    Elkin Ramiro Gaviria Muñoz, Colombia

  • Hanne Stenmose, Denmark

    Hanne Stenmose, Denmark

  • Rudiger Hanemann, Germany

    Rudiger Hanemann, Germany

  • Oscar Mauricio Linares, Colombia

    Oscar Mauricio Linares, Colombia

  • Steve

    Steve

  • Shera Mukherjee, India

    Shera Mukherjee, India

  • David Hall, USA

    David Hall, USA

  • Elkin Gaviria, Colombia

    Elkin Gaviria, Colombia

  • Enzo Maccarrone, Italy

    Enzo Maccarrone, Italy

  • Bruno Leanza Mantegna, Italy

    Bruno Leanza Mantegna, Italy

  • Chih Ching Darren Wong, Malaysia

    Chih Ching Darren Wong, Malaysia

  • Mary Thomas, Australia

    Mary Thomas, Australia

  • Valdomiro Xavier Honório, Brazil

    Valdomiro Xavier Honório, Brazil

  • Gisli Jonasson, Iceland

    Gisli Jonasson, Iceland

  • Sharon Corosanite, USA

    Sharon Corosanite, USA

  • Verónica Isabel Castro Molina, Argentina

    Verónica Isabel Castro Molina, Argentina

  • Graham Johnson, Australia

    Graham Johnson, Australia

  • Tso-Ta Huang, Taiwan

    Tso-Ta Huang, Taiwan

  • Yessenia Hernandez Mendoza, Mexico

    Yessenia Hernandez Mendoza, Mexico

  • Lombana, Spain

    Lombana, Spain

  • Duncan Bayly, Australia

    Duncan Bayly, Australia

  • Olga, Argentina

    Olga, Argentina

  • Horacio Fritzer, Argentina

    Horacio Fritzer, Argentina

  • Eddy Lefrancois, Canada

    Eddy Lefrancois, Canada

  • Orly Dichoso, Canada

    Orly Dichoso, Canada

  • Denis Blais, Canada

    Denis Blais, Canada

  • Rolf Mauch, Switzerland

    Rolf Mauch, Switzerland

  • Jose Espinosa, Argentina

    Jose Espinosa, Argentina

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login